#Preprint

Michael Eisen

mbeisen

Since the dawn of the Internet, it has been clear that we need and have the opportunity to build a system of scholarly communication free of limitations of print: a

Yea-Hung Chen

ch272n

1/9 I've been receiving some great questions re how the numbers in our preprint can be interpreted. Hopefully this thread helps clarify.https://www.medrxiv.org/content/10.1101/2021.01.21.21250266v1 2/9 Backing up a little bit, this figu

Ben

bennyoutrageous

For my non-scientist followers: this is a preprint, so it hasn’t been reviewed yet. But essentially the vaccines, both Pfizer and Moderna are significantly less effective against these highly transmissible

Arvind Narayanan

random_walker

Were you told that successful researchers must constantly "keep up" with research in their fields? In my experience, that's both stressful and inefficient to the point of being useless. New

Dr Emma Hodcroft

firefoxx66

There's been a lot of news today about 'new variants in Brazil' & 'S:E484' and 'Ohio variants'. A short thread discussing what we know about each.1/11#SARSCoV2 #Ohio #BrazilVariant #Brazil #COVID19

Sebastian Skejø

sebastianskejoe

Just published my first preprint: https://www.preprints.org/manuscript/202008.0085/v1 In this article, we (me, @jesperbencke, @Merete_Moller and Henrik Sørensen) describe our (quite long) efforts to use a wearable device (similar to the pi

BK Titanji #ILookLikeAScientist

Boghuma

Preprint-ChAdOx1 trial in HIV(-) people in South Africa. 23/717 (3.2%) placebo & 19/750 (2.5%) vaccine recipients developed mild-moderate # COVID19. Of the cases, 39/42 (92.9%) were the B.1.351 variant –

Eric Feigl-Ding

DrEricDing

Worrisome new data—new B117 variant is not only more infectious, it’s potentially more infectious in children 0-9 (+24%) and 10-19 (+14%), and less among 60-79, compared to common strains. More

Tristan Croll

CrollTristan

In all cryo-EM maps of the SARS-CoV-2 spike protein density for the N-terminal domain has been really rubbishy, with modelling only really possible based on somewhat-weak homology to the original

Dr Nisreen Alwan 🌻

Dr2NisreenAlwan

THREAD1/ This important study (preprint- not yet peer reviewed) by @patientled @AthenaAkrami @ahandvanish @GinaAssaf @LisaAMcCorkell et al offers the most detailed picture of #LongCovid symptoms to date in a relatively

Gage Moreno

GageKMoreno

Our updated #SARSCoV2 in cats preprint is now available @ https://www.biorxiv.org/content/10.1101/2020.11.16.384917v2.full.pdf+html this time with an emphasis on Spike H655Y! A (1/7)@KATarinambraun @tcfriedrich @dho I won't get into th

Adriano Aguzzi

AdrianoAguzzi

The twittermob is aflame because of Rudi Jänisch's preprint: https://www.biorxiv.org/content/10.1101/2020.12.12.422516v1 . Here is my take:1. I've known Rudi Jänisch for 35 years. I can vouch that he is among the

Samuel Brown

DrSamuelBrown

Some thoughts about the RECOVERY-DEX preprint. First, some more clarity about why it stopped--it hit the target sample size. Oddly, no discussion about alpha spend or what the DSMB reviewed.

Peter Foster

pmdfoster

Remember the government wanting to "follow the science"? It is remarkable how far it is ignoring scientific advice on this new ultra-infectious variant of #Covid-19 by keeping schools open... both

Emily Willingham

ejwillingham

Science journalism, in practice, covering a new study. 1. Read study.2. Contact study authors.3. Spend forever finding the just-right sources who can speak with authority&expertise on the study&have no association

Petros Ligoxygakis

LigoxygakisLab

The evidence on the new SARS-CoV2 variant considered by NervTag was 1) growth rate from genomic data (increased growth rate); 2) studies of R-values and detection of the variant (suggested

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.